
Chimp Haven, the world's largest chimpanzee sanctuary
Spread out across 200 acres in Northwest Louisiana, Chimp Haven is the world's largest chimpanzee sanctuary. Every detail, from the moat to the meal plan, has been designed to ensure the more than 300 residents here are getting the most out of their retirement years.
"A lot of the chimpanzees that are here, they spent decades in biomedical research before coming to sanctuary, but Chimp Haven provides their happy endings," said Rana Smith, the president and CEO of Chimp Haven.
"Chimpanzees have been used in research for decades," Smith explained. "So, back in the 1950s and 1960s, they were part of the NASA space program, and in the '70s, kind of moved into infectious disease."
Chimpanzees were instrumental in the development of everything from rocket ships to the Hepatitis B vaccine. In the 1980s, they were used in HIV research. But, precisely because of how similar they are to us, attitudes about chimp research began to change — in 2000, Congress passed the CHIMP Act, establishing a sanctuary system to care for retired research chimpanzees.
At the time, lawmakers introduced the Act as a "humane" piece of legislation meant to protect "a group who have no lobby." It required the National Institutes of Health to kick in 75% of the funding for retirees, which isn't peanuts. It costs around $25,000 a year to care for each chimp, with donations supplementing federal funds. The banana budget alone is impressive — they go through 117,000 of them a year.
Colony Director Michelle Reininger, like all staff at Chimp Haven, knows each of the chimps by name. Reininger said, for her, their personalities set these animals apart from any other species.
"I like the sassy ones," she said. "I like the ones who you have to really work hard to get them to respond to you, and to trust you. When you get that trust, there's no feeling like it in the world, to have that bond with an animal."
Days at the sanctuary are full of head scratches and lots of lazing around. The animals also receive regular checkups from veterinarian Raven Jackson.
"Chimpanzee medicine is challenging," Jackson said. "It's like working with a really strong toddler. And so, I always say, each day I start with, 'Am I smarter than a chimp?'"
There are days when Jackson feels outsmarted.
"I work for them and they don't work for me," she laughed.
Since Jackson's patients were retired at different ages, and a few are rescues or former pets, she treats a wide variety of conditions. Some of the chimps are as young as 7, while others are in their mid-60s.
"We see the full gamut," Jackson said. "It keeps things very interesting. And I think it also keeps things interesting for the chimpanzees, because we're able to put them in these very dynamic social groupings where you're going to see various age ranges."
Each of the 30 or so groups has its own characteristics and alpha leader. They don't always get along, but they're quick to make up.
"They always want to reconcile very quickly," said Jackson. "It taught me, hey, it isn't worth holding onto anything. Like, learn from the chimps. Let it go. Reconcile, so that you can continue to move forward as a group."
Moving forward a sanctuary like Chimp Haven may one day be unnecessary. Ten years ago, the NIH announced that it would no longer support any biomedical research on chimpanzees.
While there are still some new arrivals — chimps that labs had initially deemed too challenging to move — eventually there will no longer be chimpanzees "retiring" from careers they never chose.
Asked whether humans owe a debt to the chimpanzees, Smith replied: "Chimpanzees have given so much of their life to science. And we feel like it's our responsibility, and the government's responsibility to care for those chimps for the rest of their life."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
an hour ago
- Business Upturn
Novotech Showcased in Global Biotech Series for Innovation in Hepatitis B Research
Sydney, Australia: Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions. This press release features multimedia. View the full release here: Novotech, a global (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by BIO and produced by BBC StoryWorks Commercial Productions. The Next Frontier explores how biotechnology is addressing some of the world's most urgent health and sustainability challenges. As part of the series, Novotech highlights its partnership with Tune Therapeutics in advancing a functional cure for Hepatitis B, a chronic disease impacting nearly 300 million people globally. As the global leader in Hepatitis clinical trials, Novotech brings deep therapeutic expertise and global execution capabilities to accelerate development and delivery for sponsors. Filmed in New Zealand with world-leading hepatologist Professor Edward Gane, where an estimated 100,000 people are living with Hepatitis B, the feature highlights Novotech's partnership model for supporting biotech and small to mid-size pharma sponsors. It demonstrates how Novotech accelerates clinical development through access to expert investigators, targeted patient populations, and efficient trial infrastructure across Asia-Pacific, Europe, and North America, while showcasing its global capabilities in infectious disease research and trial delivery. 'Our inclusion in this series reflects Novotech's commitment to supporting innovators with smarter, faster, and more regionally tailored clinical solutions,' said Tom Hickey, Director of Therapeutic Strategy. 'Hepatitis B remains a significant global health challenge, and our teams are proud to have such a long history contributing to meaningful progress in this area.' The series will officially launch at the BIO International Convention in Boston on June 16, 2025, and is now available globally via digital platforms at . About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Yahoo
2 hours ago
- Yahoo
Future of NASA Scientific Balloon Facility in Palestine in question due to proposed budget cuts
PALESTINE, Texas (KETK) – The future of the NASA's balloon launches at the Columbia Scientific Balloon Facility in Palestine is coming into question due to proposed budget cuts for 2026. PHOTOS: Inside NASA's Columbia Scientific Balloon Facility near Palestine According to a NASA 2026 budget technical supplement released on Tuesday, cuts are being made to the the NASA Astrophysics Research program to align with President Donald Trump's Budget Request for 2026. These cuts include the Balloons, Astrophysics Data Analysis Program, which would have it's 2026 budget eliminated entirely. In a statement shared with KETK by a NASA scientist at the Columbia Scientific Balloon Facility in Palestine, NASA officials urged calm because they are still in the budget negotiation process. The Palestine facility launches 15 scientific balloons for NASA each year and is a NASA funded federal facility that would close without federal funding. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 hours ago
- Yahoo
Axiom-4 mission launch scrubbed as SpaceX detects leak in Falcon 9 rocket
June 10 (UPI) -- The Axiom-4 mission launch, the fourth private astronaut mission to the International Space Station, was canceled for a second time Tuesday after SpaceX detected a liquid oxygen leak in its Falcon 9 rocket. SpaceX announced Tuesday night in a post on X that it was "standing down" from Wednesday's launch of Axiom-4. "Standing down from tomorrow's Falcon 9 launch of Ax-4 to the space station to allow additional time for SpaceX teams to repair the LOx leak identified during post static fire booster inspections." "Once complete -- and pending Range availability -- we will share a new launch date." SpaceX scrubbed the first liftoff scheduled for Tuesday morning, due to high winds at NASA's Kennedy Space Center in Florida. Falcon 9 was rescheduled to launch Axiom-4 at 8 a.m. EDT on Wednesday, with a backup window available at 7:37 a.m. Thursday. Axiom Space, which is based in Houston, is building the first commercial space station, which is scheduled to deploy sometime before 2030. The four astronauts, who make up the mission, include Peggy Whitson, 65, a former NASA astronaut and director of human spaceflight at Axiom Space. Whitson will command the commercial mission. Shubhanshu Shukla with the Indian Space Research Organization will pilot. Mission specialists with the European Space Agency include Sławosz Uznański-Wiśniewski of Poland and Tibor Kapu of Hungary. The Axiom-4 mission is scheduled to last 14 days, as the crew conducts 60 science experiments and demonstrations "focused on human research, Earth observation and life, biological and material sciences," according to SpaceX. The Axiom-3 mission launched from the Kennedy Space Center on Jan. 18, 2024, for the first commercial spaceflight of European citizens.